These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

208 related articles for article (PubMed ID: 36649314)

  • 1. Structural basis of ferroportin inhibition by minihepcidin PR73.
    Wilbon AS; Shen J; Ruchala P; Zhou M; Pan Y
    PLoS Biol; 2023 Jan; 21(1):e3001936. PubMed ID: 36649314
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Structure-function analysis of ferroportin defines the binding site and an alternative mechanism of action of hepcidin.
    Aschemeyer S; Qiao B; Stefanova D; Valore EV; Sek AC; Ruwe TA; Vieth KR; Jung G; Casu C; Rivella S; Jormakka M; Mackenzie B; Ganz T; Nemeth E
    Blood; 2018 Feb; 131(8):899-910. PubMed ID: 29237594
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The molecular basis of hepcidin-resistant hereditary hemochromatosis.
    Fernandes A; Preza GC; Phung Y; De Domenico I; Kaplan J; Ganz T; Nemeth E
    Blood; 2009 Jul; 114(2):437-43. PubMed ID: 19383972
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Resistance to hepcidin is conferred by hemochromatosis-associated mutations of ferroportin.
    Drakesmith H; Schimanski LM; Ormerod E; Merryweather-Clarke AT; Viprakasit V; Edwards JP; Sweetland E; Bastin JM; Cowley D; Chinthammitr Y; Robson KJ; Townsend AR
    Blood; 2005 Aug; 106(3):1092-7. PubMed ID: 15831700
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Deciphering the molecular basis of ferroportin resistance to hepcidin: Structure/function analysis of rare SLC40A1 missense mutations found in suspected hemochromatosis type 4 patients.
    Le Tertre M; Ka C; Guellec J; Gourlaouen I; Férec C; Callebaut I; Le Gac G
    Transfus Clin Biol; 2017 Nov; 24(4):462-467. PubMed ID: 28826751
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Evidence for dimerization of ferroportin in a human hepatic cell line using proximity ligation assays.
    Rishi G; Secondes ES; Wallace DF; Subramaniam VN
    Biosci Rep; 2020 May; 40(5):. PubMed ID: 32301493
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Impact of D181V and A69T on the function of ferroportin as an iron export pump and hepcidin receptor.
    Praschberger R; Schranz M; Griffiths WJ; Baumgartner N; Hermann M; Lomas DJ; Pietrangelo A; Cox TM; Vogel W; Zoller H
    Biochim Biophys Acta; 2014 Sep; 1842(9):1406-12. PubMed ID: 24859227
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Identification of Guanosine 5'-diphosphate as Potential Iron Mobilizer: Preventing the Hepcidin-Ferroportin Interaction and Modulating the Interleukin-6/Stat-3 Pathway.
    Angmo S; Tripathi N; Abbat S; Sharma S; Singh SS; Halder A; Yadav K; Shukla G; Sandhir R; Rishi V; Bharatam PV; Yadav H; Singhal NK
    Sci Rep; 2017 Jan; 7():40097. PubMed ID: 28054602
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Hepcidin-Ferroportin Interaction Controls Systemic Iron Homeostasis.
    Nemeth E; Ganz T
    Int J Mol Sci; 2021 Jun; 22(12):. PubMed ID: 34204327
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Structures of ferroportin in complex with its specific inhibitor vamifeport.
    Lehmann EF; Liziczai M; Drożdżyk K; Altermatt P; Langini C; Manolova V; Sundstrom H; Dürrenberger F; Dutzler R; Manatschal C
    Elife; 2023 Mar; 12():. PubMed ID: 36943194
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cellular catabolism of the iron-regulatory peptide hormone hepcidin.
    Preza GC; Pinon R; Ganz T; Nemeth E
    PLoS One; 2013; 8(3):e58934. PubMed ID: 23536837
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Disruption of the hepcidin/ferroportin regulatory circuitry causes low axial bone mass in mice.
    Ledesma-Colunga MG; Baschant U; Fiedler IAK; Busse B; Hofbauer LC; Muckenthaler MU; Altamura S; Rauner M
    Bone; 2020 Aug; 137():115400. PubMed ID: 32380257
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The iron-regulatory hormone hepcidin: a possible therapeutic target?
    Rochette L; Gudjoncik A; Guenancia C; Zeller M; Cottin Y; Vergely C
    Pharmacol Ther; 2015 Feb; 146():35-52. PubMed ID: 25205158
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Alternative splicing generates a novel ferroportin isoform with a shorter C-terminal and an intact iron- and hepcidin-binding property.
    Juneja P; Rashid N; Abul Qais F; Tanwar S; Sultan I; Ahmad F; Rehman SU
    IUBMB Life; 2024 Aug; 76(8):523-533. PubMed ID: 38348962
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Therapeutic potential of hepcidin - the master regulator of iron metabolism.
    Vyoral D; Jiri Petrak
    Pharmacol Res; 2017 Jan; 115():242-254. PubMed ID: 27867027
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Minihepcidins are rationally designed small peptides that mimic hepcidin activity in mice and may be useful for the treatment of iron overload.
    Preza GC; Ruchala P; Pinon R; Ramos E; Qiao B; Peralta MA; Sharma S; Waring A; Ganz T; Nemeth E
    J Clin Invest; 2011 Dec; 121(12):4880-8. PubMed ID: 22045566
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The molecular basis of ferroportin-linked hemochromatosis.
    De Domenico I; Ward DM; Nemeth E; Vaughn MB; Musci G; Ganz T; Kaplan J
    Proc Natl Acad Sci U S A; 2005 Jun; 102(25):8955-60. PubMed ID: 15956209
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Mice with hepcidin-resistant ferroportin accumulate iron in the retina.
    Theurl M; Song D; Clark E; Sterling J; Grieco S; Altamura S; Galy B; Hentze M; Muckenthaler MU; Dunaief JL
    FASEB J; 2016 Feb; 30(2):813-23. PubMed ID: 26506980
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The role of ubiquitination in hepcidin-independent and hepcidin-dependent degradation of ferroportin.
    De Domenico I; Lo E; Yang B; Korolnek T; Hamza I; Ward DM; Kaplan J
    Cell Metab; 2011 Nov; 14(5):635-46. PubMed ID: 22019085
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Iron Availability in Tissue Microenvironment: The Key Role of Ferroportin.
    Gammella E; Correnti M; Cairo G; Recalcati S
    Int J Mol Sci; 2021 Mar; 22(6):. PubMed ID: 33804198
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.